Novel agents, combinations and sequences for the treatment of advanced renal cell carcinoma: When is the revolution coming?

Current Cancer Drug Targets

Volumn 13, Issue 3, 2013, Pages 313-325

  Santoni, Matteo ^a   Rizzo, Mimma ^b   Burattini, Luciano ^a   Berardi, Rossana ^a   Cartenì, Giacomo ^b   Cascinu, Stefano ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b CARDARELLI HOSPITAL   (Italy)

Author keywords

Clinical trials; Combined targeted therapy; Novel targeted agents; Renal cell carcinoma; Sequential targeted therapy

Indexed keywords

AFLIBERCEPT; AXITINIB; AZD 8055; CARBONATE DEHYDRATASE IX; CD70 ANTIGEN; CEDIRANIB; ETARACIZUMAB; FIBROBLAST GROWTH FACTOR RECEPTOR; GIRENTUXIMAB; LINIFANIB; MONOCLONAL ANTIBODY; NOTCH1 RECEPTOR; PANITUMUMAB; PLACEBO; PROTEIN KINASE B BETA; PROTEIN KINASE B INHIBITOR; RAMUCIRUMAB; REGORAFENIB; RILOTUMUMAB; SARACATINIB; SORAFENIB; STAT3 PROTEIN; SUNITINIB; TIVOZANIB; TREBANANIB; UNINDEXED DRUG; VERY LATE ACTIVATION ANTIGEN 5; VOLOCIXIMAB;

ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DIARRHEA; DISEASE COURSE; DYSPHONIA; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; IMMUNOTHERAPY; KIDNEY CARCINOMA; MULTICENTER STUDY (TOPIC); PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMATITIS; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG ADMINISTRATION SCHEDULE; DRUGS, INVESTIGATIONAL; HUMANS; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, FIBROBLAST GROWTH FACTOR; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84876887206     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/1568009611313030009     Document Type: Article

References (65)

1. Motzer, R.J.; Bacik, J.; Murphy, B.A.; Russo, P.; Mazumdar, M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol. 2002, 20 (1), 289-296.
2. McDermott, D.F.; Regan, M.M.; Clark, J.I.; Flaherty, L.E.; Weiss, G.R.; Logan, T.F.; Kirkwood, J.M.; Gordon, M.S.; Sosman, J.A.; Ernstoff, M.S.; Tretter, C.P.; Urba, W.J.; Smith, J.W.; Margolin, K.A.; Mier, J.W.; Gollob, J.A.; Dutcher, J.P.; Atkins, M.B. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2005, 23 (1), 133-141.
3. Heng, D.Y.; Xie, W, Regan, M.M.; Warren, M.A.; Golshayan, A.R.; Sahi, C.; Eigl, B.J.; Ruether, J.D.; Cheng, T.; North, S.; Venner, P.; Knox, J.J.; Chi, K.N.; Kollmannsberger, C.; McDermott, D.F.; Oh, W.K.; Atkins, M.B.; Bukowski, R.M.; Rini, B.I.; Choueiri, T.K. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J. Clin. Oncol. 2009, 27 (34), 5794-5799.
4. Rixe, O.; Bukowski, R.M.; Michaelson, M.D.; Wilding, G.; Hudes, G.R.; Bolte, O.; Motzer, R.J.; Bycott, P.; Liau K.F.; Freddo J.; Trask P.C.; Kim S.; Rini, B.I. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet 2007, 8 (11), 975-984.
5. Rini, B.I.; Escudier, B.; Tomczak, P.; Kaprin, A.; Szczylik, C.; Hutson, T.E.; Michaelson, M.D.; Gorbunova, V.A.; Gore, M.E.; Rusakov, I.G.; Negrier, S.; Ou, YC.; Castellano, D.; Lim, H.Y.; Uemura, H.; Tarazi, J.; Cella, D.; Chen, C.; Rosbrook, B.; Kim, S.; Motzer, R.J. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011, 378 (9807), 1931-1939.
6. Nosov, D.A.; Esteves, B.; Lipatov, O.N.; Lyulko, A.A.; Anischenko, A.A.; Chacko, R.T.; Doval, D.C.; Strahs, A.; Slichenmyer, W.J.; Bhargava, P. Antitumor Activity and Safety of Tivozanib (AV-951) in a Phase II Randomized Discontinuation Trial in Patients With Renal Cell Carcinoma. J. Clin. Oncol. 2012, 30 (14), 1678-1685.
7. Mulders, P.; Hawkins, R.; Nathan, P.; de Jong, I.; Osanto, S.; Porfiri, E.; Protheroe, A.; van Herpen, C.M.; Mookerjee, B.; Pike, L.; Jürgensmeier, J.M.; Gore, M.E. Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study. Eur. J. Cancer 2012, 48 (4), 527-537.
8. Tannir, N.M.; Wong, Y.N.; Kollmannsberger, C.K.; Ernstoff, M.S.; Perry, D.J.; Appleman, L.J.; Posadas, E.M.; Cho, D.; Choueiri, T.K.; Coates, A.; Gupta, N.; Pradhan, R.; Qian, J.; Chen, J.; Scappaticci, F.A.; Ricker, J.L.; Carlson, D.M.; Michaelson, M.D. Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. Eur. J. Cancer 2011, 47 (18), 2706-2714.
9. Eisen, T.; Joensuu, H.; Nathan, P.D.; Harper, P.G.; Wojtukiewicz, M.Z.; Nicholson, S.; Bahl, A.; Tomczak, P.; Pyrhonen, S.; Fife, K.; Bono, P.; Boxall, J.; Wagner, A.; Jeffers, M.; Lin, T.; Quinn, D.I. Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma:a single-group phase 2 trial. Lancet Oncol. 2012, 13 (10), 1055-1062.
10. Jermann, M.; Stahel, R.A.; Salzberg, M.; Cerny, T.; Joerger, M.; Gillessen, S.; Morant, R.; Egli F.; Rhyner, K.; Bauer J.A.; Pless, M. A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma. Cancer Chemother. Pharmacol. 2006, 57 (4), 533-539.
11. Shek, D.; Longmate, J.; Quinn, D.I.; Margolin, K.A.; Twardowski, P.; Gandara, D.R.; Frankel, P.; Pan, C.X.; Lara, P.N. Jr. A phase II trial of gefitinib and pegylated IFNβ in previously treated renal cell carcinoma. Int. J. Clin. Oncol. 2011, 16 (5), 494-499.
12. Shepard, D.R.; Cooney, M.M.; Elson, P.; Bukowski, R.M.; Dreicer, R.; Rini, B.I.; Garcia J.A. A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma. Invest. New Drugs 2012, 30 (1), 364-367.
13. Mita, M.; Mita, A.C.; Chu, Q.C.; Rowinsky, E.K.; Fetterly, G.J.; Goldston, M.; Patnaik, A.; Mathews, L.; Ricart, A.D.; Mays, T.; Knowles, H.; Rivera, V.M.; Kreisberg, J.; Bedrosian, C.L.;Tolcher, A.W. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J. Clin. Oncol. 2008, 26, 361-367.
14. Cho, D.C.; Cohen, M.B.; Panka, D.J.; Collins, M.; Ghebremichael, M.; Atkins, M.B.; Signoretti, S.; Mier, J.W. The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin. Cancer Res. 2010, 16 (14), 3628-3638.
15. Welti, J.C.; Gourlaouen, M.; Powles, T.; Kudahetti, S.C.; Wilson, P.; Berney, D.M.; Reynolds, A.R. Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib. Oncogene 2011, 30 (10), 1183-1193.
16. McNeel, D.G.; Eickhoff, J.; Lee, F.T.; King, D.M.; Alberti, D.; Thomas, J.P.; Friedl, A.; Kolesar, J.; Marnocha, R.; Volkman, J.; Zhang, J.; Hammershaimb, L.; Zwiebel, J.A.; Wilding, G. Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. Clin. Cancer. Res. 2005, 11 (21), 7851-7860.
17. Spratlin, J.L.; Cohen, R.B.; Eadens, M.; Gore, L.; Camidge, D.R.; Diab, S.; Leong, S.; O'Bryant, C.; Chow, L.Q.M.; Serkova, N.J.; Meropol, N.J.; Lewis, N.L.; Chiorean, E.G.; Fox, F.; Youssoufian, H.; Rowinsky, E.K.; Eckhardt S.G. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J. Clin. Oncol. 2010, 28, 780-787.
18. Verheul, H.M.W.; Hammers, H.; Van Erp, K.; Wei, Y.; Sanni, T.; Salumbides, B.; Qian, D.Z.; Yancopoulos, G.D.; Pili, R. Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model. Clin. Cancer Res. 2007, 13 (14), 4201-4208.
19. Fukuhara, S.; Sako, K.; Noda, K.; Zhang, J.; Minami, M.; Mochizuki, N. Angiopoietin-1/Tie2 receptor signaling in vascular quiescence and angiogenesis. Histol. Histopathol. 2010, 25 (3), 387-396.
20. Huang, H.; Bhat, A.; Woodnutt, G.; Lappe, R. Targeting the ANGPT-TIE2 pathway in malignancy. Nat. Rev. Cancer 2010, 10 (8), 575-585.
21. Rini, B.; Szczylik, C.; Tannir, N.M.; Koralewski, P.; Tomczak, P.; Deptala, A.; Dirix, L.Y.; Fishman, M.; Ramlau, R.; Ravaud, A.; Rogowski, W.; Kracht, K.; Sun, Y.N.; Bass, M.B.; Puhlmann, M.; Escudier, B. AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: A randomized, double-blind, placebo-controlled, phase 2 study. Cancer 2012, Jun 12. doi: 10.1002/cncr.27632.
22. Law, C.L.; Gordon, K.A.; Toki, B.E.; Yamane, A.K.; Hering, M.A.; Cerveny, C.G.; Petroziello, J.M.; Ryan, M.C.; Smith, L.; Simon, R.; Sauter, G.; Oflazoglu, E.; Doronina, S.O.; Meyer, D.L.; Francisco, J.A.; Carter, P.; Senter, P.D.; Copland, J.A.; Wood, C.G.; Wahl, A.F. Lymphocyte Activation Antigen CD70 Expressed by Renal Cell Carcinoma Is a Potential Therapeutic Target for Anti-CD70 Antibody-Drug Conjugates. Cancer Res. 2006, 66 (4), 2328-2337.
23. Oosterwijk, E.; Ruiter, D.J., Hoedemaeker, P.J.; Pauwels, E.K.; Jonas, U.; Zwartendijk, J.; Warnaar, S.O. Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int. J. Cancer 1986, 38 (4), 489-494.
24. Liu, Z.; Smyth, F.E.; Renner, C.; Lee, F.T.; Oosterwijk, E.; Scott, A.M. Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity. Cancer Immunol. Immunother. 2002, 51 (3), 171-177.
25. Schöffski, P.; Garcia, J.A.; Stadler, W.M.; Gil, T.; Jonasch, E.; Tagawa, S.T.; Smitt, M.; Yang, X.; Oliner, K.S.; Anderson, A.; Zhu, M.; Kabbinavar, F. A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma. B.J.U. Int. 2011, 108 (5), 679-686.
26. Rowinsky, E.K.; Schwartz, G.H.; Gollob, J.A.; Thompson, J.A.; Vogelzang, N.J.; Figlin, R.; Bukowski, R.; Haas, N.; Lockbaum, P.; Li, Y.P.; Arends, R.; Foon, K.A.; Schwab, G.; Dutcher, J. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human antiepidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J. Clin. Oncol. 2004, 22 (15), 3003-3015.
27. Parker, A.S.; Lohse, C.M.; Wu, K.; Kreinest, P.; Copland, J.A.; Hilton, T.; Wehle, M.; Cheville, J.C.; Blute, M. Lower expression levels of the transforming growth factor beta receptor type II protein are associated with a less aggressive tumor phenotype and improved survival among patients with clearcell renal cell carcinoma. Hum. Pathol. 2007, 38 (3), 453-461.
28. Kouzarides T. Histone acetylases and deacetylases in cell proliferation. Curr. Opin. Genet. Dev. 1999, 9 (1), 40-48.
29. Hainsworth, J.D.; Infante, J.R.; Spigel, D.R.; Arrowsmith, E.R.; Boccia, R.V.; Burris, H.A. A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma. Cancer Invest. 2011, 29 (7), 451-455.
30. Stadler, W.M.; Margolin, K.; Ferber, S.; McCulloch, W.; Thompson, J.A. A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin. Genitourin. Cancer 2006, 5 (1), 57-60.
31. Iso, T.; Hamamori, Y.; Kedes, L. Notch signaling in vascular development. Arterioscler. Thromb. Vasc. Biol. 2003, 23 (4), 543-553.
32. Liu, Z.J.; Shirakawa, T.; Li, Y.; Soma, A.; Oka, M.; Dotto, G.P.; Fairman, R.M.; Velazquez, O.C.; Herlyn, M. Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis. Mol. Cell. Biol. 2003, 23 (1), 14-25.
33. Ireson, C.R.; Kelland, L.R. Discovery and development of anticancer aptamers. Mol. Cancer Ther. 2006, 5 (12), 2957-2962.
34. Ginisty, H.; Sicard, H.; Roger, B.; Bouvet, P. Structure and functions of nucleolin. J. Cell Sci. 1999, 112 (6), 761-772.
35. Soundararajan, S.; Chen, W.; Spicer, E.K.; Courtenay-Luck, N.; Fernandes, D.J. The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells. Cancer Res. 2008, 68 (7), 2358-2365.
36. Rini, B. I; Michaelson, M.D.; Rosenberg, J.E.; Bukowski, R.M.; Sosman, J.A.; Stadler, W.M.; Hutson, T.E.; Margolin, K.; Harmon, C.S.; DePrimo, S.E.; Kim, S.T.; Chen, I.; George, D.J. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J. Clin. Oncol. 2008, 26 (22), 3743-3748.
37. Di Lorenzo, G.; Carteni, G.; Autorino, R.; Bruni, G.; Tudini, M.; Rizzo, M.; Aieta, M.; Gonnella, A.; Rescigno, P.; Perdonà, S.; Giannarini, G.; Pignata, S.; Longo, N.; Palmieri, G.; Imbimbo, C.; De Laurentiis, M.; Mirone, V.; Ficorella, C.; De Placido, S. Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J. Clin. Oncol. 2009, 27 (27), 4469-4474.
38. Porta, C.; Procopio, G.; Cartenì, G.; Sabbatini, R.; Bearz, A.; Chiappino, I., Ruggeri, E.M.; Lo Re, G.; Ricotta, R.; Zustovich, F.; Landi, L.; Calcagno, L.; Imarisio, I.; Verzoni, E.; Rizzo, M.; Paglino, C.; Guadalupi, V.; Bajetta, E. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases. B.J.U. Int. 2011, 108 (8 Pt 2), E250-E257.
39. Dudek, A.Z.; Zolnierek, J.; Dham, A.; Lindgren, B.R.; Szczylik, C. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 2009, 115, 6167.
40. Sablin, M.P.; Negrier, S.; Ravaud, A.; Oudard, S.; Balleyguier, C.; Gautier, J.; Celier, C.; Medioni, J.; Escudier, B. Sequential sorafenib and sunitinib for renal cell carcinoma. J. Urol. 2009, 182 (1), 29-34.
41. Eichelberg, C.; Heuer, R.; Chun, FK.; Hinrichs, K.; Zacharias, M.; Huland, H.; Heinzer, H. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib inmetastatic renal cell carcinoma: a retrospective outcome analysis. Eur. Urol. 2008, 54 (6), 1373-1378.
42. Tamaskar, I.; Garcia, J.A.; Elson, P.; Wood, L.; Mekhail, T.; Dreicer, R.; Rini, B.I.; Bukowski, R.M. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J. Urol. 2008, 179, 81-86.
43. Zimmermann, K.; Schmittel, A.; Steiner, U.; Asemissen, A.M.; Knoedler, M.; Thiel, E.; Miller, K.; Keilholz, U. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology 2009, 76, 350-354.
44. Di Lorenzo, G.; Casciano, R.; Malangone, E.; Buonerba, C.; Sherman, S.; Willet, J.; Wang, X.; Liu, Z.; De Placido, S. An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples. Expert. Opin. Pharmacother. 2011, 12 (10), 1491-1497.
45. Feldman, D.R.; Baum, M.S.; Ginsberg, S.;Hassoun, H.; Flombaum, C.D.; Velasco, S.; Fischer, P.; Ronnen, E.; Ishill, N.; Patil, S.; Motzer, R.J. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2009, 27 (9), 1432-1439.
46. Rini, B.I.; Garcia, J.A.; Cooney, M.M.; Elson, P.; Tyler, A.; Beatty, K.; Bokar, J.; Mekhail, T.; Bukowski, R.M.; Budd, G.T.; Triozzi, P.; Borden, E.; Ivy, P.; Chen, H.X.; Dolwati, A.; Dreicer, R. A phase I study of sunitinib plus bevacizumab in advanced solid tumors. Clin. Cancer Res. 2009, 15 (19), 6277-6283
47. Bukowski, R.M.; Kabbinavar, F.F.; Figlin, R.A.; Flaherty, K.; Srinivas, S.; Vaishampayan, U.; Drabkin, H.A.; Dutcher, J.; Ryba, S.; Xia, Q.; Scappaticci, F.A.; McDermott, D. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J. Clin. Oncol. 2007, 25 (29), 4536-4541.
48. Hainsworth, J.D.; Spigel, D.R.; Sosman, J.A.; Burris, H.A. 3rd.; Farley, C.; Cucullu, H.; Yost, K.; Hart, L.L.; Sylvester, L.; Waterhouse, D.M.; Greco, F.A. Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial. Clin. Genitourin. Cancer 2007, 5 (7), 427-432.
49. Hainsworth JD, Spigel DR, Burris HA 3rd, Waterhouse D, Clark BL, Whorf R. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J. Clin. Oncol. 2010, 28 (13), 2131-2136.
50. Négrier, S.; Gravis, G.; Pérol, D.; Chevreau, C.; Delva, R.; Bay, J.O.; Blanc, E.; Ferlay, C.; Geoffrois, L.; Rolland, F.; Legouffe, E.; Sevin, E.; Laguerre, B.; Escudier, B. Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. Lancet Oncol. 2011, 12 (7), 673-680.
51. Motzer, R.J.; Hudes, G.R.; Ginsberg, M.S.; Baum, M.S.; Harmon, C.S.; Kim, S.T.; Chen, I.; Redman, B.G. Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma. Am. J. Clin. Oncol. 2010, 33 (6), 614-618.
52. Harzstark, A.L.; Rosenberg, J.E.; Weinberg, V.K.; Sun, J.; Ryan, C.J.; Lin, A.M.; Fong, L.; Brocks, D.R.; Rosenberg, J.E. A phase I study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma. Cancer 2011, 117 (18), 4194-4200.
53. Patel, P.H.; Senico, P.L.; Curiel, R.E.; Motzer, R.J. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin. Genitourin. Cancer 2009, 7 (1), 24-27.
54. Roulin, D.; Waselle, L.; Dormond-Meuwly, A.; Dufour, M.; Demartines, N.; Dormond, O. Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib. Mol. Cancer 2011, 10, 90.
55. Flaig, T.W.; Costa, L.J.; Gustafson, D.L.; Breaker, K.; Schultz, M.K.; Crighton, F.; Kim, F.J.; Drabkin H. Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib. Br. J. Cancer 2010, 103 (6), 796-801.
56. Jiang, X.J.; Meng, F.Y.; Huang, K.K.; Zhou, H.S.; Wang, Q. Effect of RAD001 or plus LBH589 on the proliferation, apoptosis and drug resistance in chemoresistant acute myeloid leukemic cells. Zhonghua Yi Xue Za Zhi 2011, 91 (32), 2287-2292.
57. Mizushima, N.; Levine, B.; Cuervo, A.M.; Klionsky, D.J. Autophagy fights disease through cellular self-digestion. Nature 2008, 451 (7182), 1069-1075.
58. Lopez-Beltran, A.; Scarpelli, M.; Montironi, R.; Kirkali, Z. WHO classification of the renal tmors of the adults. Eur. Urol. 2006, 49, 798-805.
59. Upton, M.P.; Parker, R.A.; Youmans, A.; McDermott, D.F.; Atkins, M.B. Histologic predictors of renal cell carcinoma response to interleukine-2-based therapy. J. Immunother. 2005, 28 (5), 488-495.
60. Bono, P.; Rautiola, J.; Utriainen, T.; Joensuu, H. Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma. Acta Oncologica, 2011, 50, 569-573.
61. Farace, F.; Gross-Goupil3, M.; Tournay, E.; Taylor, M.; Vimond, N.; Jacques, N.; Billiot, F.; Mauguen, A.; Hill, C.; and Escudier, B. Levels of circulating CD45dimCD34pVEGFR2p progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors. Br. J. Cancer, 2011, 104, 1144-1150.
62. Kalantari, H.R. Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br. J. Can. 2009, 101, 1222-1223.
63. Tonini, G.; Fratto, M.E.; Imperatori, M.; Pantano, F.; Vincenti, B.; and Santini D. Predictive factors of response to treatment in patients with metastatic renal cell carcinoma: new evidence. Expert Rev. Anticancer Ther. 2011, 11 (6), 921-930.
64. Garcia-Donas, J.; Esteban, E.; Leandro-García, L.J.; Castellano, D.E. González del Alba, A.; Climent, M.A.; Arranz, J.A.; Gallardo, E.; Puente, J.; Bellmunt, J.; Mellado, B.; Martínez, E.; Moreno, F.; Font, A.; Robledo, M.; Rodríguez-Antona, C. Single nucleotide polymorphism associations with response and toxic eff ects in patients with advanced renal-cell carcinoma treated with fi rst-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol. 2011, 12, 1143-1150.
65. Gruenwald, V.; Beute, G.; Schuch-Jantsch, S.; Reuter, C.; Ivanyi, P.; Ganser, A.; Haubitz, M. Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib. BMC Cancer 2010, 10, 695.